Copper(ii) Complexes with Reduced Schiff Base: Synthesis, Spectroscopic, Thermal, X-Ray, and Cytotoxic Studies of Novel Copper(ii) Complexes with an Arylpyrazole Ligand
Vukadin M. Leovac A , Petra Bombicz B , Katalin Mészáros Szécsényi A and Milan D. Joksović D DA Faculty of Sciences, University of Novi Sad, Trg D. Obradovića 3, 21000 Novi Sad, Serbia.
B Institute of Structural Chemistry, Chemical Research Center, Hungarian Academy of Sciences, PO Box 17, H-1525 Budapest, Hungary.
C Faculty of Sciences, University of Kragujevac, R. Domanovica 12, 34000 Kragujevac, Serbia.
D Corresponding author. Email: mjoksovic@kg.ac.yu
Australian Journal of Chemistry 60(8) 615-620 https://doi.org/10.1071/CH07183
Submitted: 30 May 2007 Accepted: 6 July 2007 Published: 9 August 2007
Abstract
The synthesis of a novel arylpyrazole-derived ligand, 1,2-bis[(1,3-diphenylpyrazol-4-yl)methyl]diaminoethane (Ph4Pz2mde), and its complexes prepared with CuCl2 [Cu(Ph4Pz2mde)Cl2(MeOH)] 1, CuBr2 [Cu(Ph4Pz2mde)Br2(MeOH)] 2, from MeOH, and [Cu(Ph4Pz2mde)Cl2(DMF)] 3, from a mixture of MeOH and DMF, are described. The complexes are characterized by elemental and thermal analysis and FT-IR spectroscopy, while the 1H and 13C NMR assignments are given for the ligand. The crystal and molecular structure of [Cu(Ph4Pz2mde)Cl2(DMF)] was determined by single-crystal X-ray diffraction. In-vitro cytotoxicity of the Ph4Pz2mde ligand and two copper(ii) complexes was obtained using sulforhodamine B (SRB) treatment against three human tumour cell lines: HeLa (epitheloid carcinoma of cervix), MCF-7 (breast adenocarcinoma), and MRC-5 (lung fetal fibroblasts).
Acknowledgments
A diffractometer purchase grant from the Hungarian National Office for Research and Technology (MU-00338/2003) is gratefully acknowledged. This work was financed by the Ministry for Science and Environmental Protection of the Republic of Serbia (grant no. 142028) and the Provincial Secretariat for Science and Technological Development of Vojvodina. We also thank Ms Gordana Bogdanović and Ms Vesna Kojić, Institute of Oncology, Experimental Oncology Department, Sremska Kamenica, Serbia for biological evaluation of our synthesized compounds.
[1]
K. L. Kees,
J. J. Fitzgerald,
K. E. Steiner,
J. F. Mattes,
B. Mihan,
T. Tosi,
D. Mondoro,
M. L. McCaleb,
J. Med. Chem. 1996, 39, 3920.
| Crossref | GoogleScholarGoogle Scholar |
| Crossref | GoogleScholarGoogle Scholar |
| Crossref | GoogleScholarGoogle Scholar |
| Crossref | GoogleScholarGoogle Scholar |
| Crossref | GoogleScholarGoogle Scholar |
| Crossref | GoogleScholarGoogle Scholar |
| Crossref | GoogleScholarGoogle Scholar |
| Crossref | GoogleScholarGoogle Scholar |
| Crossref | GoogleScholarGoogle Scholar |
| Crossref | GoogleScholarGoogle Scholar |
| Crossref | GoogleScholarGoogle Scholar |
| Crossref | GoogleScholarGoogle Scholar |
| Crossref | GoogleScholarGoogle Scholar |
| Crossref | GoogleScholarGoogle Scholar |
| Crossref | GoogleScholarGoogle Scholar |
| Crossref | GoogleScholarGoogle Scholar |
| Crossref | GoogleScholarGoogle Scholar |
| Crossref | GoogleScholarGoogle Scholar |
| Crossref | GoogleScholarGoogle Scholar |
| Crossref | GoogleScholarGoogle Scholar |
| Crossref | GoogleScholarGoogle Scholar |
| Crossref | GoogleScholarGoogle Scholar |
[30]
[31]
[32]